Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Shah, N. N.; Wang, M. L.; Brown, J. R.; Patel, K.; Woyach, J. A.; Wierda, W. G.; Ujjani, C. S.; Eyre, T. A.; Zinzani, P. L.; Alencar, A. J.; Gastinne, T.; Ghia, P.; Lamanna, N.; Hoffmann, M.; Patel, M. R.; Flinn, I. W.; Gerson, J. N.; Ma, S.; Coombs, C. C.; Cheah, C. Y.; Lech-Maranda, E.; Fakhri, B.; Kim, W. S.; Barve, M. A.; Cohen, J. B.; Jurczak, W.; Munir, T.; Thompson, M. C.; Roeker, L. E.; Bao, K.; Cangemi, N. A.; Kherani, J. F.; Walgren, R. A.; Han, H. M.; Ruppert, A. S.; Mato, A. R. |
| Abstract Title: | Safety and tolerability of pirtobrutinib monotherapy in patients with B-cell malignancies who were previously intolerant to a covalent BTK inhibitor: Results from the phase 1/2 BRUIN study |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 4127 |
| End Page: | 4132 |
| Language: | English |
| ACCESSION: | WOS:000893223204062 |
| DOI: | 10.1182/blood-2022-159035 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
